Navigation Links
Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Date:10/1/2009

PARIS, Oct. 1 /PRNewswire/ -- Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases. The deal is valued to a total of euro 370M, including an immediate upfront payment and subsequent milestone payments related to the progress of the clinical compounds. The closing of the transaction is expected to occur in the 4th quarter of 2009.

Fovea was created in 2005 by Professeur Jose A. Sahel, Bernard Gilly and Pierre Belichard, with the initial seeding of Sofinnova Partners in Paris. It successfully raised two rounds of funding in November 2005 and February 2008, from a syndicate of pan-european investors including Sofinnova Partners, Abingworth Management, Forbion Capital Partners, The Wellcome Trust, GIMV, Credit Agricole Private Equity and Vesalius BioCapital.

Fovea has rapidly built a pipeline of products: FOV 1101, an eye drop, fixed dose combination of prednisolone and cyclosporine, currently in phase II for the treatment of persistent allergic conjunctivitis, FOV 2302, an intravitreal formulation of a plasma kallikrein inhibitor, in phase I for the treatment of Retinal Vein Occlusion induced macular edema and FOV 2304, a potent antagonist of bradykinin B1 receptor, active by eye drop, scheduled to enter in phase I by November 2009 for the treatment of diabetic macular oedema.

"Our team is proud and extremely pleased to join sanofi-aventis, as it will provide the necessary resources and expertise needed to continue to aggressively build the ophthalmology franchise and demonstrate the efficacy of our products through regulatory clinical development," commented Bernard Gilly, President and Chief Executive Officer of Fovea Pharmaceuticals. "It also demonstrates that strong science combi
'/>"/>

SOURCE Fovea Pharmaceuticals SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
2. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
3. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
4. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
5. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
6. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
8. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
9. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
10. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
11. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015 Today, humanity takes a ... the singularity, and fat-free cronuts: 1-800 CONTACTS announces their new ... in just two taps. Two taps. New contacts. ... The app also features LensGauge which helps keep ... when you need to reorder. "Since our inception, ...
(Date:4/24/2015)... April 24, 2015  A new study shows an "alarming ... drugs used to slow the progression of multiple sclerosis or ... by researchers at Oregon Health & Science University (OHSU) and ... the number of MS drugs in the marketplace over the ... stabilized costs for patients who use those drugs. Researchers found ...
(Date:4/24/2015)... S.C. , April 24, 2015  Span-America ... plans to release its fiscal 2015 second quarter ... regular trading. The company will conduct ... Friday, May 1, to review the company,s financial and ... 2015.  A live broadcast of the conference call ...
Breaking Medicine Technology:Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2Researchers find alarming rise in cost of MS drugs over past two decades 2Researchers find alarming rise in cost of MS drugs over past two decades 3Researchers find alarming rise in cost of MS drugs over past two decades 4
... influenza,transmission patterns in the Southern Hemisphere and ... finding that,each season influenza travels from low ... populated centers. Their work, funded by the,Fogarty ... Institutes,of Health (NIH), can improve planning for ...
... - An overexpressed protein,protects human pancreatic cancer ... of the body's natural defenses against,out-of-control cell growth, ... Cancer Center report in the March issue of ... by the abbreviation,TG2, previously has been found by ...
Cached Medicine Technology:Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 2Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 3Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3
(Date:4/25/2015)... 25, 2015 By definition, a CIO’s responsibility ... the enterprise relying on their judgement and expertise to keep ... according to an article published in National Mortgage News ... be doing a disservice to their responsibilities by focusing too ... t’s are crossed when it comes to company policy and ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
(Date:4/24/2015)... 24, 2015 As the nation recognizes ... unique sacrifices of these young men and women, the ... Veterans and their Families” presents a special training session ... to gain a better understanding of the effect of ... For those – civilian and military – who provide ...
(Date:4/24/2015)... 2015 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... federal multidistrict litigation underway in U.S. District Court, ... the parties involved in the proceeding submitted a ... other things, preparation for the litigation’s upcoming bellwether ... plaintiffs and defendants have conducted depositions of non-party ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... transplants after removing small cancerous and benign masses from ... December issue of the urology journal BJUI. The ... of Maryland School of Medicine in Baltimore, could offer ... as well as increasing the supply of viable organs. ...
... Nutra Pharma ... the Food and Drug Administration (FDA). This registration is considered the final step required by ... the treatment of chronic pain. , ... Plantation, FL (Vocus) December 7, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology ...
... ... Changes in Industry Standards and Compliance Requirements , ... (PRWEB) December 7, 2009 -- BridgeGate ... the launch of its new integration technology training program, which will kick off ...
... in comparison study , SUNDAY, Dec. 6 (HealthDay ... therapy for prostate cancer are best controlled by ... according to a new study. , Androgen suppression ... prostate cancer, but about 80 percent of patients ...
... older anti-clotting drug, with fewer hassles, study finds , MONDAY, ... dabigatran etexilate may be just as effective in preventing dangerous ... for doctors and patients to manage, a new study finds. ... in Europe; it is not yet approved for use in ...
... ... offer top-of-the-line implementation services to Talyst’s clients in the acute care industry. ... (PRWEB) ... of the American Society of Health-System Pharmacists in Las Vegas, Talyst announced a ...
Cached Medicine News:Health News:Controversial kidney transplant technique could provide lifeline for very ill patients 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 2Health News:BridgeGate International Announces New Integration and Interoperability Training Program 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 4Health News:Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: